验证数据展示
经过测试的应用
Positive IF/ICC detected in | C6 cells |
推荐稀释比
应用 | 推荐稀释比 |
---|---|
Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
产品信息
CL488-66426 targets SPARC in IF/ICC applications and shows reactivity with human, Rat samples.
经测试应用 | IF/ICC Application Description |
经测试反应性 | human, Rat |
免疫原 | SPARC fusion protein Ag7390 种属同源性预测 |
宿主/亚型 | Mouse / IgG2a |
抗体类别 | Monoclonal |
产品类型 | Antibody |
全称 | secreted protein, acidic, cysteine-rich (osteonectin) |
别名 | Basement membrane protein 40, BM 40, ON, Osteonectin, SPARC |
计算分子量 | 35 kDa |
观测分子量 | 38 kDa, 52 kDa |
GenBank蛋白编号 | BC004974 |
基因名称 | SPARC |
Gene ID (NCBI) | 6678 |
RRID | AB_3672912 |
偶联类型 | CoraLite® Plus 488 Fluorescent Dye |
最大激发/发射波长 | 493 nm / 522 nm |
形式 | Liquid |
纯化方式 | Protein A purification |
UNIPROT ID | P09486 |
储存缓冲液 | PBS with 50% glycerol, 0.05% Proclin300, 0.5% BSA , pH 7.3 |
储存条件 | Store at -20°C. Avoid exposure to light. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
SPARC, also known as ON (Osteonectin) or BM-40 (Basement-membrane protein 40), is an extracellular glycoprotein with the calculated molecular mass of 35 kDa and the apparent molecular mass of 40-43 kDa and 50 kDa (PMID: 7495300, 12365801). SPARC belongs to a group of matricellular proteins defined as secreted components that do not contribute directly to the formation of structural elements but serve to modulate cell-matrix interactions and cellular functions (PMID: 7542656; 12231357). SPARC is expressed at high levels in bone tissue, is distributed widely in many other tissues and cell types, and is associated generally with tissues undergoing morphogenesis, remodeling and wound repair (PMID: 10567433). It elicits changes in cell shape, inhibits cell-cycle progression, and influences the synthesis of extracellular matrix (PMID: 12721366). Altered expression of SPARC has been reported in a variety of cancers, which include breast, ovarian, colorectal, and pancreatic cancer as well as melanoma and glioblastomas (PMID: 18849185).
实验方案
Product Specific Protocols | |
---|---|
IF protocol for CL Plus 488 SPARC antibody CL488-66426 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |